The World Health Organization issued a warning regarding fake batches of Ozempic in Europe and the U.S. the same day Eli Lilly $LLY filed lawsuits against companies selling counterfeit versions of its weight loss drug Zepbound. Gilead $GILD’s HIV prevention injection was found to work with 100% efficacy in a clinical trial. Novo Nordisk CEO Lars Fruergaard Jørgensen has agreed to voluntarily testify in September before the Senate’s health committee.
Check out those stories and more pharmaceutical news highlights from this week.
1 / 10
The World Health Organization (WHO) issued a global alert Wednesday warning the public about fake batches of Ozempic across Europe and the Americas.
2 / 10
Gilead $GILD announced that its twice-yearly injection, lenacapavir, worked with 100% efficacy at preventing HIV infections in a late-stage clinical trial.
3 / 10
The evidence is starting to pile up that Ozempic and other GLP-1 medications could help people with substance abuse disorders. Researchers from the University of North Carolina found that people with alcohol use disorder drank less after taking semaglutide, the active ingredient in Novo Nordisk’s Ozempic, compared with with people who took a placebo.
4 / 10
Eli Lilly $LLY said Thursday that it is taking legal action against six entities for selling unapproved versions of its popular weight loss and diabetes medication tirzepatide — the generic name of Mounjaro and Zepbound.
5 / 10
Stelara, Comirnaty, Sronyx — why are drug names often so strange? It’s actually primarily due to safety. Settling on a name can take a drug manufacturer up to four years and involves several regulatory agencies.
6 / 10
The tech entrepreneur who once had his son’s plasma infused with his blood in an attempt to extend his own life now claims that he successfully slowed the aging process by undergoing an untested DNA editing procedure on a Honduran island.
7 / 10
Novo Nordisk CEO Lars Fruergaard Jørgensen has agreed to voluntarily testify in September before the Senate’s health committee to address the pharma giant’s high prices for its diabetes and weight loss drugs in the U.S.
8 / 10
In another ripple effect on the economy, Ozempic and other weight loss drugs are boosting sales of smaller-sized clothes.
9 / 10
David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly $LLY, says that food, diet, and fitness companies have called him for advice regarding the growing popularity of the company’s diabetes and weight loss drugs.
